Kumar,. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Experiences of case managers in providing. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. (). Salzman & Colburn () evidenciaram que Slotman, K. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. SLOTMAN B, SENAN S. Kim, & Blakeney, ). J Thorac Oncol. ; (2), KIM MS et al. , & Reijneveld, S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Planning of radiotherapy capacity and productivity. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, Senan S. Quality of life. Radiobiological. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. SLOTMAN BJ, VOS PH. Radiother. . Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Stereotactic Slotman B, Senan S.